Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Hans-Ulrich Demuth


Hans-Ulrich Demuth

Fraunhofer Institute for Cell Therapy and Immunology, Germany

Biography

Hans-Ulrich Demuth has completed his PhD at the age of 28 and his doctorate of sciences at the age of 36 years from Martin-Luther-University, Halle/S., Germany. He did postdoctoral studies at University of Kansas and the Uppsala Biomedical Research Center. He has inaugurated and co-founded Probiodrug in 1997, the company which has developed the concept of inhibition of Dipeptidylpeptidase-4 as treatment of type-2 diabetes (on the market since 2006). He has published more than 300 papers in reputed journals and has been serving as an editorial board member and reviewer of repute. In 2013 he founded the Fraunhofer-IZI department MWT.

Abstract

Abstract : Targeting Neurotoxic N-Terminal Pyroglutamated Abeta (Pgluaβ) with inhibitors of Glutaminyl Cyclase (Qc) and Pgluaβ-specific antibodies has reached clinical stage